Vifor Pharma offers to fix alleged anti-competitive behaviour
Zydus Lifesciences on Friday said it has acquired rights to market MonoFerric (iron isomaltoside) injections in India and Nepal from Denmark based Pharmacosmos.
Zydus Lifesciences has acquired rights to market MonoFerric (iron isomaltoside) injections in India and Nepal from Denmark-based Pharmacosmos A/S. MonoFerric 1000 solution for injection/infusion is a rapid, single-dose IV iron (up to 20 mg/kg bodyweight) developed to reduce the number of infusions required to achieve iron correction with an excellent safety profile, according to a statement from Zydus.
Five years after Danish Pharmacosmos entered a strategic collaboration with Japanese partner Nippon Shinyaku on the launch of Monover (ferric derisomaltose) in Japan, the two parties can now initiate the marketing efforts in the country.
Danish biotech Pharmacosmos has come a long way since it was launched back in 1965 as an active pharmaceutical ingredient (API) manufacturer. While it’s still in the same family, the company now has three drugs approved to treat iron deficiency in humans (and a fourth for piglets).
Pharmacosmos Therapeutics Inc. announced today that it has been established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric® for Iron Deficiency Anemia (IDA) patients in the US. The new company is a subsidiary of the Pharmacosmos Group, a profitable, fast-growing specialty pharmaceutical company headquartered in Denmark.
Pharmacosmos Therapeutics Inc. announced today that it has been established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric® for Iron Deficiency Anemia (IDA) patients in the US. The new company is a subsidiary of the Pharmacosmos Group, a profitable, fast-growing specialty pharmaceutical company headquartered in Denmark.